期刊文献+

凉血活血汤联合阿维A胶囊治疗银屑病的临床疗效及其机制研究 被引量:13

Effects and Mechanisms of Cool Blood Huoxue Soup Combined with Avi A Capsule on Psoriasis
原文传递
导出
摘要 目的:探讨凉血活血汤联合阿维A胶囊治疗银屑病的临床疗效及其可能作用机制。方法:选择2012年7月~2015年11月于我院就诊的银屑病患者60例,按照就诊先后顺序分为实验组与对照组,每组各30例,实验组患者使用凉血活血汤联合阿维A胶囊进行治疗,对照组患者仅给予阿维A胶囊进行治疗。比较治疗前后两组患者血清白细胞介素17(IL-17)、白细胞介素22(IL-22)、白细胞介素23(IL-23)及血管内皮因子(VEGF)水平,同时比较两组患者的不良反应发生率及临床总有效率。结果:与治疗前相比,两组患者血清IL-17、IL-22、IL-23及VEGF水平均降低;治疗结束后与对照组相比,实验组患者血清IL-17、IL-22、IL-23及VEGF水平较低(P〈0.05);且与对照组相比,实验组患者的不良反应发生率较低(P〈0.05);临床总有效率较高(P〈0.05)。结论:凉血活血汤联合阿维A胶囊能明显提高银屑病患者的临床疗效,且安全性较高,可能与其降低血清IL-17、IL-22、IL-23及VEGF水平有关。 Objective: To investigate the effect of IL- 22 vascular endothelial growth factor and clinical curative effect cool blood huoxue soup combined with avi A capsule in patients with psoriasis. Methods: A total of 60 patients with psoriasis from July 2012 to November 2015 in our hospital were collected and randomly divided into the experimental group and control group with 30 cases in each group. Patients in the experimental group were treated by cool blood huoxue soup combined with avi A capsule, patients in the control group were treated by avi A capsule. Compared the serum interleukin 17(IL-17), interleukin(IL-22) 22, interleukin 23(IL-23) and vascular endothelial factor(VEGF) levels in the two groups between before treatment and after treatment, at the same time in the treatment process of adverse situations were recorded, and compared the incidence of adverse reactions and clinical total effective rate between the two groups. Results: Compared with before treatment, two groups of patients’ serum IL-17, IL-22, IL-23 and VEGF levels were lower;compared with control group, the experimental group patients serum IL-17, IL-22, IL-23 and VEGF levels were lower after treatment(P〈0.05); And compared with the control group, the experimental group patients incidence of adverse reactions were lower(P〈 0.05);The clinical total effective rate was higher(P〈0.05). Conclusion: Cool blood huoxue soup combine with avi A capsule in the treatment of patients with psoriasis can reduce the adverse reaction, improve clinical curative effect, speculate that the mechanism may be relate to lower serum IL-17 patients, IL-22, IL-23 and VEGF levels.
出处 《现代生物医学进展》 CAS 2016年第27期5283-5286,共4页 Progress in Modern Biomedicine
基金 陕西省自然科学基金项目(2010JM4020)
关键词 凉血活血汤 阿维A胶囊 银屑病 IL-22 血管内皮生长因子 Cool blood huoxue soup Avi A capsule Psoriasis IL-22 Vascular endothelial growth factor
  • 相关文献

参考文献20

  • 1Parisi R, Symmons D P M, Cn'iffiths C E M, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence[J]. Jour- nal of Investigative Dermatology, 2013, 133(2): 377-385.
  • 2Langley R G, Elewski B E, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials [J]. New England Journal of Medicine, 2014, 371(4): 326-338.
  • 3Papp K A, Langley R G, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose ranging study[J]. British Journal of Dermatology, 2013, 168(2): 412-421.
  • 4Armstrong A W, Harskamp C T, Armstrong E J. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis[J]. JAM& dermatology, 2013, 149(1): 84-91.
  • 5Armstrong A W, Harskamp C T, Armstrong E J. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of obser- vational studies [J]. Journal of the American Academy of Dermatolo- gy, 2013, 68(4): 654-662.
  • 6Papp K A, C_niffiths C E M, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final re- suits fi'om 5 years of follow-up [J]. British Journal of Dermatology, 2013, 168(4): 844-854.
  • 7Martin D A, Towne J E, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings [J]. Journal of Investigative Dermatology, 2013, 133(1): 17-26.
  • 8Tzellos T, Kyrgidis A, Zouboulis C C. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with an- ti-IL-12/23 biological agents for chronic plaque psoriasis: a meta- analysis of randomized controlled trials [J]. Journal of the European Academy of Dermatology and Venereology, 2013, 27(5): 622-627.
  • 9Yeuag H, Takeshita J, Meitta N N, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study [J]. JAMA dermatology, 2013, 149(10): 1173-1179.
  • 10Armstrong A W, Robertson A D, Wu J, et al. Undertreatment, treat- ment trends, and treatment di ssati sfacti on among patients with psori a- sis and psoriatic arthritis in the United States: findings from the Na- tional Psoriasis Foundati on surveys, 2003-2011 [J]. JAMA dermatology, 2013, 149(10): 1180-1185.

同被引文献159

引证文献13

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部